Skip to Content
DiagnosticsDiagnostics
  • Review
  • Open Access

20 November 2026

28 Pages

Hybrid PET/CCTA for Coronary Atherosclerosis: Molecular Targets, Technical Challenges, and Clinical Translation

,
,
,
,
,
and
1
ARS Nuclear Medicine Clinic, LV-1002 Riga, LatviaARS Nuclear Medicine Clinic, Medical Society “ARS” Ltd., 13 Gardenes Street, LV-1002 Riga, Latvia
2
Faculty of Medicine and Life Sciences, University of Latvia, Jelgavas Street 3, LV-1004 Riga, Latvia
3
Riga East Clinical University Hospital, 2 Hipokrata Street, LV-1038 Riga, Latvia
4
Pauls Stradins Clinical University Hospital, 13 Pilsonu Street, LV-1002 Riga, Latvia
Diagnostics2026, 16(22), 3903;https://doi.org/10.3390/diagnostics16223903 
(registering DOI)
This article belongs to the Special Issue Current Advances in Cardiovascular Imaging

Abstract

Coronary computed tomography angiography (CCTA) characterizes luminal stenosis and plaque morphology, whereas positron emission tomography (PET) can depict biological processes involved in atherosclerosis. Hybrid PET/CCTA enables assessment of tracer uptake in relation to coronary anatomy, but its interpretation and clinical translation remain challenging. This narrative review, based on a non-systematic, topic-focused literature search, examines established and emerging molecular imaging targets, including inflammation, microcalcification, fibroblast activation, hypoxia, angiogenesis, and thrombosis. We discuss tracer-specific evidence, quantitative measurements, reproducibility, and the effects of cardiac and respiratory motion, partial-volume loss, background activity, and image misregistration. We distinguish human coronary findings from evidence obtained in other vascular territories or preclinical studies. We describe an institutional acquisition workflow, accompanied by illustrative FDG and NaF PET/CCTA images showing CCTA-defined coronary atherosclerosis without discernible focal tracer uptake. [18F]NaF has the most extensive human coronary evidence among the tracers reviewed. However, associations between uptake and subsequent events do not establish the benefit of PET-guided management. Tracer uptake alone does not indicate impending plaque rupture, and the absence of uptake does not establish plaque stability. Standardized acquisition and quantification, validation of incremental value beyond contemporary CCTA, and evidence of improved patient outcomes are required before routine clinical adoption.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.